

This entry is our account of a study collected by Drug and Alcohol Findings. Citation here does not imply that the document is particularly relevant to Britain and of particular merit, though it may well be both. Unless indicated otherwise, permission is given to distribute this entry or incorporate passages in other documents as long as the source is acknowledged including the web address <http://findings.org.uk>. The original study was not published by Findings; click on the [Title](#) to obtain copies. Free reprints may also be available from the authors – click [Request reprint](#) to send or adapt the pre-prepared e-mail message. Links to source documents are in [blue](#). Hover mouse over [orange](#) text for explanatory notes. The Summary is intended to convey the findings and views expressed in the study. Below are some comments from Drug and Alcohol Findings.

Click [HERE](#) and enter e-mail address to be alerted to new studies and reviews

► [Favorable mortality profile of naltrexone implants for opiate addiction.](#)

Reece A.S.

Journal of Addictive Diseases: 2010, 29, p. 30–50.

[Request reprint](#) using your default e-mail program or write to Dr Reece at sreece@bigpond.net.au

Few treatments for opiate addiction arouse as much controversy as naltrexone implants. Inserted under the skin, these block the effects of heroin for up to several months - for some, a magic bullet, for others, an unsafe and ethically dubious experiment. More evidence from Australia that the overdose death risk is less than with oral forms of the drug.

Summary At an Australian addiction treatment clinic the death rate of opiate-dependent patients treated with the heroin substitute buprenorphine between 2000 and 2007 was compared with those treated with implants of naltrexone which block the effects of heroin and allied drugs for up to several months. During this time 2518 patients were prescribed buprenorphine free of charge (though there were pharmacy charges) and 255 were implanted, mostly at their own expense. Records were matched with those of deaths recorded by the registrar of the relevant Australian state.

Main findings

Four naltrexone and 43 buprenorphine patients were known to have died. There were no deaths while a naltrexone implant was active but four among patients in whom the implant would no longer have been effective, resulting in an overall death rate of three deaths for every 1000 years the patients had been tracked. For buprenorphine the corresponding figure was 5.35, largely due to 40 deaths during times when the patients were not being prescribed the drug. Generally the death rate in each age band was lower for the naltrexone patients. All but one of the four naltrexone deaths occurred several months after the implant would no longer have been effective.

The authors' conclusions

The major finding of the current study was that in terms of death rates, naltrexone implants compared favourably under most comparisons: with the same clinic's

experience of buprenorphine, with the Perth methadone programme, and even with Australian national population age-adjusted death figures. This was the case despite the fact that buprenorphine is a treatment widely recognised as safe and effective.

Another important finding was the utility of long-acting forms of naltrexone implants to promote treatment retention in a group of patients who tend to avoid traditional indefinite substitute prescribing programmes.

FINDINGS

As with any abstinence-based treatment, relapse risking overdose due to lost tolerance to opiate-type drugs is a serious concern after naltrexone implants have lost their effectiveness. However, studies to date of naltrexone implants **suggest** these protect against overdose while they are active, and that in caseloads prepared to undertake these procedures, opiate overdose reductions can outlast the active period of the implants. The featured study is in line with this literature, which together suggests that implant and injectable long-acting forms of naltrexone are a major advance on oral naltrexone in safety and effectiveness in curbing illicit opiate use. However, the literature is small and methodologically weak. Reviewing it in 2010, the Australian government's National Health and Medical Research Council **remained unconvinced** of the safety or effectiveness of the implants and the long-term overdose risk after the treatment has ended. Their conclusion was that implants should "only be used in the context of a well conducted [randomised controlled trial] with sufficient sample size, appropriate duration of treatment and follow up, regular robust monitoring, provision of a comprehensive psychosocial treatment [programme], and with comparison to current best practice".

A criticism of trials to date is that they included highly selected patients. However, in this they may have reflected normal practice. Patients will only opt for such procedures if they are prepared (irreversibly in the case of depot injections) to commit to possibly weeks or months without the effects of heroin or other opiate-type drugs. From the control groups in naltrexone implant/depot studies, we know that even in these caseloads, treatment drop-out and relapse are common. Long-acting naltrexone helps these highly motivated patients sustain their resolve.

The clearest candidates for the treatment are patients who are motivated (perhaps because due to employment or other pressures, they have to) to return to a life without opiate-type drugs including prescribed substitutes, have the resources, stability and support to sustain this, are unlikely to simply use other drugs instead, but who when free to experience heroin and allied drugs, cannot resist using them, possibly reflected in their poor compliance with oral naltrexone regimens. The treatment may also **be considered** for unstable patients at very high risk of overdose, but who will not accept or do poorly in substitute prescribing programmes. Other candidates might include those unwilling or unable to accept daily supervised consumption if this is a requirement of being prescribed substitute medications.

As the featured study hints, it would not be justified to conclude from its findings that for any given patient or across a population, naltrexone implants which block heroin's effects are safer than buprenorphine which substitutes for heroin. Substitute prescribing, which 'goes with the grain' of the patient's addiction, has mass appeal. Without it, many addicts would not enter treatment, especially if the step had to be as steep as from opiate use several times a day every day, to no opiate use (or at least, no effects) for months. Different kinds of patients are attracted to and suitable for these different treatments;

they might also have differed in their life expectancies even without treatment, and forced to accept the other option, might not have done as well as patients who chose it and/or were considered suitable.

In the featured study in particular, implant patients were the minority prepared not just to accept, but willing and able to pay for a procedure which would mean they could not experience opiate-type effects for up to several months. Additionally, buprenorphine patients spent very little time in treatment – just 14% of the time from when they started to the end of the study period. As detailed in [another report](#) on the same patients, at just 16 days the **typical** treatment duration on buprenorphine is suggestive of poor retention, and on average the patients were in and out of treatment three or four times. Retention was particularly and significantly worse among the buprenorphine patients who died. Counselling, was offered but not at the prescribing clinic, and few patients took up the offer. It seems likely that at this clinic the buprenorphine comparator was not implemented in a sufficiently supportive way to hold patients in treatment and exert the full protective effect. Set against this, long-acting naltrexone implants virtually ensured retention in an active pharmacotherapy for up to several months.

In the UK, neither implants nor depot injections of naltrexone have been licensed for medical use; they can still be (and have been; [1](#) [2](#) [3](#) [4](#)) used, but patient and doctor have to accept the added responsibility of a product which has not yet been shown to meet the safety and efficacy requirements involved in licensing.

Naltrexone implants and depot injections impede opiate-based pain relief. This is a greater problem with the irreversible long-acting naltrexone injection than with implants which can be removed. Possible adverse effects of naltrexone on liver function are also [a concern](#) based on early studies, but not one confirmed in several later studies.

This draft entry is currently subject to consultation and correction by the study authors and other experts.

Last revised 25 July 2012

[► Comment on this entry](#) ► [Give us your feedback on the site \(one-minute survey\)](#)

Unable to obtain the document from the suggested source? Here's an [alternative](#).

Top 10 most closely related documents on this site. For more try a [subject or free text search](#)

[Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial](#) STUDY 2011

[Naltrexone implants compared to methadone: outcomes six months after prison release](#) STUDY 2010

[Pharmacotherapies for the treatment of opioid dependence: efficacy, cost-effectiveness and implementation guidelines](#) REVIEW 2009

[Opiate antagonist treatment risks overdose](#) STUDY 2004

[Naltrexone implants prevent opiate overdose](#) STUDY 2006

[High risk of overdose death for opiate detoxification completers](#) STUDY 2008

[Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial](#) STUDY 2008

[Naltrexone implants after in-patient treatment for opioid dependence: randomised controlled trial](#) ABSTRACT

2009

[Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone](#) STUDY 2009

[Long-acting depot naltrexone extends opiate abstinence](#) STUDY 2006